Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
February 29 2024 - 9:00AM
Business Wire
– Applications for the 2024-2025 academic year will be
accepted until May 13, 2024
– Scholarships will be awarded to up to 20 individuals
living with Duchenne muscular dystrophy and up to five siblings of
individuals living with Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, today announced the
official opening of Route 79, The Duchenne Scholarship Program for
the 2024-2025 academic year. Academic scholarships of up to $5,000
will be awarded to as many as 20 individuals living with Duchenne
muscular dystrophy and five siblings of individuals living with
Duchenne.
Applications will be accepted until Monday, May 13, 2024, at
11:59 p.m. PDT. Recipients will be notified prior to August 2024
and awards will be distributed directly to the school, college or
university in time for fall 2024 enrollment. Students may learn
more about the program and how to apply by visiting
sarepta.com/route79.
“Sarepta is proud to announce the opening of Route 79, The
Duchenne Scholarship Program for the 2024-2025 academic year. In
recognition of the magnitude a Duchenne muscular dystrophy
diagnosis brings to the entire household, we continue to invite
students who live with Duchenne or have a sibling who lives with
Duchenne to apply as they pursue their educational goals for the
year,” said Diane Berry, Ph.D., Sarepta’s Executive Vice President
and Chief Global Policy & Advocacy Officer. “The Route 79
program embodies Sarepta's unwavering commitment to the Duchenne
community and helps nurture brighter futures. Every year, we are
profoundly moved by each applicant’s narrative and dedication to
their educational pursuits. We are excited to learn about this
year’s pool of applicants and look forward to supporting our
growing community of Route 79 scholars.”
To apply for a scholarship through the Route 79 program,
applicants must be accepted to or enrolled in an accredited college
or university, or a trade, technical or vocational school located
in the United States. Only applicants diagnosed with Duchenne or
applicants who have a sibling diagnosed with Duchenne are eligible
for the program. College seniors or college graduates accepted to
or enrolled in graduate school are also eligible to apply. Previous
recipients of Route 79 scholarships may apply for the 2024
Scholarship Program, however, applicants may only receive a Route
79 scholarship up to four times. No consideration is given to
whether an applicant was previously, is currently, or expects to be
in the future, undergoing treatment with a Sarepta product or
investigational therapy. For additional applicant criteria, please
visit www.sarepta.com/route79.
About Route 79, The Duchenne Scholarship Program
The Route 79 program is designed to help students living with
Duchenne and siblings of individuals living with Duchenne pursue
their post-secondary educational goals. Scholarship recipients are
chosen by an independent committee of Duchenne community members
based on an applicant’s community involvement, personal essay, and
recommendation letter. The underlying cause of Duchenne is a
mutation or error in the gene coding for dystrophin. Dystrophin is
an essential protein that plays a pivotal role in muscle structure,
function and preservation. The numerical significance of the
scholarship’s name, Route 79, ties to the 79 exons of the
dystrophin gene. For more information, visit
sarepta.com/route79.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic
medicine for rare diseases that devastate lives and cut futures
short. We hold leadership positions in Duchenne muscular dystrophy
(DMD) and limb-girdle muscular dystrophies (LGMDs), and we
currently have more than 40 programs in various stages of
development. Our vast pipeline is driven by our multi-platform
Precision Genetic Medicine Engine in gene therapy, RNA and gene
editing. For more information, please visit www.sarepta.com or
follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors
in the 'For Investors' section of our website at www.sarepta.com.
We encourage investors and potential investors to consult our
website regularly for important information about us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229172355/en/
Investor Contact: Ian Estepan, 617-274-4052
iestepan@sarepta.com Media Contacts: Tracy Sorrentino,
617-301-8566 tsorrentino@sarepta.com Sierra Smith, 617-710-1385
sismith@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024